Teva Says U.S. FDA Approves Aerosol Treatment of Nasal Allergies

Teva Pharmaceutical Industries Ltd. (TEVA) said the U.S. Food and Drug Administration has approved its QNASL nasal aerosol for the treatment of nasal allergies. The product will be available by prescription in April 2012, Teva said in a Business Wire statement today.

To contact the reporter on this story: Shoshanna Solomon in Tel Aviv at ssolomon22@bloomberg.net

To contact the editor responsible for this story: Gwen Ackerman at gackerman@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.